Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis

Respiratory Investigation

Volumn 55, Issue 1, 2017, Pages 16-23

  Wakamatsu, Kentaro ^a   Nagata, Nobuhiko ^b   Kumazoe, Hiroyuki ^a   Oda, Keishi ^c   Ishimoto, Hiroshi ^c   Yoshimi, Michihiro ^d   Takata, Shohei ^d   Hamada, Minako ^e   Koreeda, Yoshifusa ^e   Takakura, Kouji ^a   Ishizu, Miwa ^a   Hara, Makiko ^a   Ise, Shinji ^a   Izumi, Miiru ^a   Akasaki, Takashi ^a   Maki, Sanae ^a   Kawabata, Masaharu ^e   Mukae, Hiroshi ^c   Kawasaki, Masayuki ^a  

^a Omuta National Hospital   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e Department of Respiratory Medicine   (Japan)

Author keywords

Forced vital capacity; Idiopathic pulmonary fibrosis; Prognosis; Serum KL 6 levels

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLYCOPROTEIN; IMMUNOSUPPRESSIVE AGENT; KL 6; PREDNISOLONE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MUC1 PROTEIN, HUMAN; MUCIN 1; PIRFENIDONE; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MALE; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; SURVIVAL; BLOOD; FOLLOW UP; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MUCIN-1; PROGNOSIS; PYRIDONES; RETROSPECTIVE STUDIES;

EID: 85008249130     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2016.09.003     Document Type: Article

References (18)

1. [1] Kohno, N., Kyoizumi, S., Awaya, Y., et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 96 (1989), 68–73.
2. [2] Kobayashi, J., Kitamura, S., KL-6: a serum marker for interstitial pneumonia. Chest 108 (1995), 311–315.
3. [3] Yokoyama, A., Kohno, N., Hamada, H., et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158 (1998), 1680–1684.
4. [4] Kohno, N., Hamada, H., Fujioka, S., et al. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest 102 (1992), 117–122.
5. [5] Hamada, H., Sakatani, M., Ueda, E., A study on the utility of KL-6, a marker for interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 34 (1996), 771–777.
6. [6] Ishikawa, N., Hattori, N., Yokoyama, A., et al. Utility of KL-6/MUC 1 in the clinical management of interstitial lung diseases. Respir Investig 50 (2012), 3–13.
7. [7] Zhang, Y., Kaminski, N., Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 18 (2012), 441–446.
8. [8] Collard, H.R., Calfee, C.S., Wolters, P.J., et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 299 (2010), L3–L7.
9. [9] du Bois, R.M., Weycker, D., Albera, C., et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 184 (2011), 1382–1389.
10. [10] Takahashi, H., Shiratori, M., Kanai, A., et al. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology 11 (2006), S51–S54.
11. [11] Yokoyama, A., Kondo, K., Nakajima, M., et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11 (2006), 164–168.
12. [12] Taniguchi, H., Ebina, M., Kondoh, Y., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35 (2010), 821–829.
13. [13] Raghu, G., Collard, H.R., Egan, J.J., et al. An Official ATS/ERS/JRS/ALAT Statement: idiopathic Pulmonary Fibrosis: evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 183 (2011), 788–824.
14. [14] Japanese Respiratory Society׳s Committee formulating diagnosis and treatment guideline for diffuse lung diseases. Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonias., 2004, Nankodo, Tokyo, 63–65.
15. [15] Kohno, N., Akiyama, M., Kyoizumi, S., et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18 (1988), 203–216.
16. [16] Collard, H.R., Moore, B.B., Flaherty, K.R., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 (2007), 636–643.
17. [17] Sakamoto, K., Taniguchi, H., Kondoh, Y., et al. Serum KL-6 in fibrotic NSIP: correlations with physiologic and radiologic parameters. Respir Med 104 (2010), 127–133.
18. [18] Ohshimo, S., Ishikawa, N., Horimasu, Y., et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med 108 (2014), 1031–1039.